Antenatal Testing and Blood-Borne Viruses (BBVs)

This resource is for health professionals providing women with antenatal care, including midwives, general practitioners and obstetricians. It contains advice about recommended antenatal testing for the three major blood-borne viruses (BBVs): hepatitis B (HBV), hepatitis C (HCV) and human immunodeficiency virus (HIV). In addition, it provides information about the management of these BBVs during pregnancy and at delivery.

This is a document designed for nationwide use and is therefore necessarily broad. It is advisable to read this in conjunction with local policy and procedures regarding BBV testing and management in pregnancy.

Further information on HBV, HCV and HIV is available on the Australasian Society for HIV Medicine (ASHM) website (www.ashm.org.au).
Epidemiology in the Antenatal Population and Mode of Transmission

Chronic HBV affects between 240 and 350 million people worldwide. In Australia, antenatal testing data suggest a prevalence of CHB of between 1 and 2%, being higher in women born overseas in endemic areas, and among Aboriginal and Torres Strait Islander women. HBV is endemic in many of the countries of origin of culturally and linguistically diverse (CALD) communities. In Australia, high rates of chronic HBV are seen in CALD communities from South East Asia and North East Asia. Aboriginal and Torres Strait Islander populations also have a higher prevalence of chronic HBV than the general population.

HBV is transmitted by contact with infected blood or body fluids. HBV may be transmitted vertically from mother-to-child; horizontally through close contact usually in childhood; via blood exposure such as injecting drug use (IDU), unsafe tattooing and piercing and through unprotected sex.

Effect of HBV on Pregnancy

There are conflicting reports regarding whether HBV is associated with greater risk of obstetric or perinatal outcomes. There is no evidence that acute HBV in pregnancy increases mortality or is teratogenic, but a higher incidence of low-birth weight and prematurity has been reported. Hepatocellular carcinoma (HCC) is rare in pregnancy, but in the limited number of reports published on this, it has been associated with high-maternal mortality.

Effect of Pregnancy on HBV

Generally, pregnant women with chronic HBV remain stable during pregnancy but those with cirrhosis should be monitored for any deterioration. Advanced liver disease is uncommon in pregnancy, however if present, complications such as coagulation disturbances may create difficulties during pregnancy and delivery. A proportion of women will have hepatitis flares, most commonly in the early postpartum period. There are also limited data suggesting a higher than expected rate of e antigen (eAg) clearance in the months following delivery, possibly related to pregnancy induced immunological changes although not all studies have confirmed this finding.

Mother-to-Child Transmission (MTCT)

Most mother-to-child transmission (MTCT) of HBV occurs during the process of labour and birth. The most important determinant of transmission is the presence of eAg. Without interventions, up to 90% of children born to HBV e antigen (HBeAg) positive women acquire the infection, compared to less than 10% of those born to HBeAg negative women. This can be reduced by up to 95% with administration of HBV immunoglobulin (HBIG) and HBV vaccine to the exposed infant. Horizontal transmission (infection acquired in early childhood after delivery) is well recognised and has been attributed to father-to-child contact, sibling contact, and medical procedures such as intramuscular injections.

Antenatal HBV Screening

Universal screening for HBV is recommended by the Australasian Society of Infectious Diseases (ASID) and the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG). All pregnant women should be offered a test for HBV in pregnancy, regardless of previous testing or vaccination. The recommended screening test for HBV is hepatitis B surface antigen (HBsAg). This should be offered at the first antenatal visit. Universal screening is preferred over selective screening, as a substantial number of cases will be missed with a selective approach.

All women identified as infected with HBV during pregnancy should be referred to an infectious diseases specialist or hepatologist for information, advice and follow-up after delivery, as they may be at risk of long-term complications of cirrhosis, liver failure and hepatocellular carcinoma. This should be done as soon as the test result is available to ensure the pregnant woman has access to appropriate medical care.

Table 1: Hepatitis B (HBV) Intervention Summary

<table>
<thead>
<tr>
<th>Recommendation for antenatal screening</th>
<th>Routine/universal screening</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk of vertical transmission with no intervention</td>
<td>10% if HBeAg negative 90% if HBeAg positive</td>
</tr>
<tr>
<td>Recommended interventions proven to reduce vertical transmission</td>
<td>HBV Immunoglobulin and HBV vaccine to infant</td>
</tr>
<tr>
<td>Benefit of intervention</td>
<td>95% reduction in risk</td>
</tr>
</tbody>
</table>
to expert advice and appropriate interpretation of additional investigations such as eAg, liver function tests and HBV viral load. It is crucial that pregnant women receive accurate and detailed information regarding the risk of HBV transmission to the infant, as well as possible interventions during pregnancy to reduce this risk, including antiviral therapy. It is also the responsibility of the health care professional to ensure sexual and/or household contacts receive counselling, testing, follow-up and vaccination, where required.

**Interventions During Pregnancy, Delivery and Postpartum**

Infants born to hepatitis B surface antigen (HBsAg) positive mothers should be given HBIG preferably within 12 hours of birth, as its efficacy decreases markedly if administration is delayed beyond 48 hours. This intervention should be discussed with the family during the pregnancy, so consent can be obtained prior to delivery. The first dose of HBV vaccine should be given at the same time as HBIG, but in the opposite thigh. Three subsequent doses of HBV vaccine should be given at two, four and either six or twelve months of age (depending on the combination vaccine used), so that the infant is given a total of four doses of HBV-containing vaccine.

There are increasing data suggesting that women with a high viral load have an increased risk (up to 8-9%) of transmitting HBV to their infants, despite the use of HBIG and HBV vaccine. In addition, antiviral therapy given in the last trimester of pregnancy has been demonstrated to reduce perinatal transmission in observational studies and in a randomised controlled trial.

In one non-randomised trial there was a lower risk of HBV transmission in the group delivered by caesarean section. These findings were not repeated in a subsequent study, which reported that caesarean section does not reduce the incidence of immunoprophylaxis failure. Most guidelines do not therefore recommend caesarean section as an intervention to reduce vertical transmission of HBV.

Standard precautions should be utilised when handling the baby. Delaying intramuscular injections until after the baby has been bathed to remove all maternal blood is generally recommended. Breastfeeding does not appear to increase the risk of HBV transmission to the infant and should not be discouraged.

The newborn should be tested for HBsAg and hepatitis B surface antibodies (Anti-HBs), three to twelve months after the final dose of HBV vaccine.

Women exposed to HBV during pregnancy should have urgent serology to test for immunity. Uninfected women who are anti-HBs negative should be given HBV vaccine and HBIG within 72 hours of a high-risk exposure. They should complete the HBV vaccination course and have testing for HBsAg at three months post exposure and provided this is negative, have routine delivery and management of the newborn.
Hepatitis C Virus (HCV)

Epidemiology in the Antenatal Population and Mode of Transmission
An estimated 230,000 people were living with chronic HCV in Australia at the end of 2013. The prevalence of HCV antibodies in the Australian antenatal population is estimated at 1.4% of pregnant women. Approximately 70% of people with HCV antibodies have ongoing viral infection as indicated by a detectable HCV RNA test. Risk factors for HCV are listed in Table 2 below.

Effect of HCV on Pregnancy
Women with HCV are generally at no greater risk of obstetric or perinatal complications than HCV uninfected women. Advanced liver disease is uncommon in pregnancy, however if present, the issues arising from this, such as coagulation disturbances, may complicate the pregnancy and delivery.

Effect of Pregnancy on HCV
Prospective studies following women with HCV during pregnancy and in the postpartum period have reported a trend to normalization of liver function tests with an increase in the HCV viral load during the third trimester of pregnancy. The viral load returns to pre-pregnancy levels in the postpartum period with the proportion of viremic women remaining unchanged. Women with HCV may be at risk of a hepatic flare in the months following delivery and should be monitored by an infectious diseases specialist or a hepatologist.

Mother-to-Child Transmission (MTCT)
The estimated rate of MTCT of HCV in viremic women is approximately 5%, although this may be higher if the woman is also infected with HIV. The exact mechanism of HCV transmission to the newborn is unknown.

Antenatal HCV Screening
The National Hepatitis C Testing Policy recommends selective antenatal screening for HCV based on identified risk factors as listed in Table 2. Other reasons for testing include maternal request after discussing risk factors and/or signs of liver disease or extra-hepatic manifestations of HCV. All testing must be confidential, voluntary, and with informed consent.

The rationale for selective screening includes the low prevalence of hepatitis C amongst pregnant women and the lack of evidence to suggest that universal screening would identify more cases than selective screening. Indeterminate and false positive results may be expected to occur in a low-prevalence population, causing unnecessary anxiety. Importantly, the risk of MTCT is low, and interventions to minimize the risk of transmission are very limited.

Treatments for HCV are contraindicated in pregnant women. Although women diagnosed antenatally may be given health advice, it is unlikely that being diagnosed whilst pregnant will result in any positive health benefit for mother or baby during the pregnancy.

Table 3: Hepatitis C (HCV) Intervention Summary

| Recommendation for antenatal screening | Selective screening based on risk factors or maternal request |
|Risk of vertical transmission | 5% if HCV RNA detected (if not also infected with HIV) |
|Recommended interventions (without strong evidence) | Avoidance of procedures that risk breaching baby’s skin or mucous membranes |
| | Expressing and discarding breast milk if nipples bleeding |

Table 2: Risk factors for HCV

- People who have ever injected drugs
- People who are, or have been, incarcerated
- Recipients of organs, tissues, blood or blood products before February 1990 in Australia, or at any time overseas
- People with tattoos or skin piercings – indications to test will include poor infection control procedures, e.g. tattooing and skin piercings which were carried out in some overseas countries or in a custodial setting
- People born in countries with high hepatitis C prevalence (Asia, Africa, Middle East, Eastern and Southern Europe)
- Sexual partners of people with hepatitis C
While the RANZCOG, in its position statement on routine antenatal assessment, recommends screening of all pregnant women for HCV infection, it does acknowledge this as a contentious area of practice. The recommended screening test for HCV is an HCV antibody using an enzyme immunoassay (EIA). All women who test positive for the HCV antibody should have confirmation with a second independent assay before they are reported as positive.

Women who are hepatitis C antibody positive require liver function tests and HCV RNA testing. Those who are HCV RNA negative are at extremely low risk of transmitting HCV to their newborn, however as HCV antibodies are not protective, they are at risk of re-infection if re-exposed.

Interventions During Pregnancy, Delivery and Postpartum

In contrast to HBV and HIV, there is little evidence that interventions during pregnancy or at the time of delivery reduce the risk of MTCT of HCV. For a woman with a diagnosis of HCV during pregnancy, referral to an infectious diseases specialist or hepatologist, as well as to hepatitis support groups for information and advice, should be made during the pregnancy. This will facilitate provision of accurate information, counselling and linkages for follow up and treatment if desired postpartum.

The role of elective caesarean section in the management of women infected with HCV remains uncertain, and further research is required before a recommendation can be made on the mode of delivery used to prevent transmission. Standard precautions and delay of intramuscular injections until after the baby has been bathed to remove all maternal blood are advised.

There is no evidence that breastfeeding is associated with an increased risk of HCV transmission to the newborn despite the detection of HCV RNA in breast milk. Consideration should be given to expressing and discarding milk if nipples are cracked and bleeding, until healed.

The infant should have an HCV antibody test at 12-18 months of age. If HCV antibody positive, the infant requires HCV RNA testing to determine if he/she is viremic, and referral to a paediatric hepatologist. Earlier detection with qualitative HCV RNA testing at 2-3 months is possible, however this is unlikely to alter the immediate clinical management of the newborn. If HCV RNA test is negative, it is recommended to have an antibody test at 18 months.
Epidemiology in the Antenatal Population and Mode of Transmission

An estimated 26,800 people were living with HIV in Australia at the end of 2013. The prevalence of HIV in pregnant women in Australia is estimated to be 0.04%. The most common mode of HIV transmission in Australia is via sexual contact. Other reported modes of transmission include vertical transmission, injecting drug use, unsafe tattooing and piercing and receipt of blood products prior to 1985. People from HIV high-prevalence countries and their sexual partners are at increased risk of HIV.

Effect of HIV on Pregnancy

Women with HIV generally have uneventful pregnancies. For women with HIV receiving antiretrovirals, the data regarding use of antiretroviral therapy (ART) and adverse pregnancy outcomes are conflicting. Some studies have found an association between ART and pre-term delivery, whilst others have not. HIV infection is not associated with fetal malformations.

Effect of Pregnancy on HIV

Pregnant women with HIV have lower CD4 counts than when they were not pregnant, due to physiological changes such as haemodilution, however the CD4 percentage remains stable. Similarly, plasma HIV viral load levels are not changed by pregnancy. Pregnant women with HIV are not at increased risk of mortality or progression to AIDS. Pregnant women should be monitored for side effects to ART, particularly hepatic dysfunction, hepatic steatosis, lactic acidosis and nevirapine hypersensitivity, all of which may be more common in pregnancy.

Mother-to-Child Transmission (MTCT)

HIV may be transmitted to the newborn during pregnancy, delivery, or via breastfeeding. Rates of transmission from mother-to-child without interventions have been reported from 13-40%.

In developed countries, where interventions such as cART, elective caesarean section and avoidance of breastfeeding are available, the rate of MTCT is reported as less than 2%. The maternal plasma HIV viral load is the most important test for determining risk of MTCT. Even though viral load is important, there is no level associated with a zero risk of transmission. In Australia from 2000 to 2009, transmission rates from mother-to-child were 1.97% for mothers aware of their HIV status prior to or at delivery, compared with 50% for those diagnosed after delivery.

Antenatal HIV Screening

Universal antenatal screening for HIV is recommended in the National HIV Testing Policy and by the RANZCOG. The screening test for HIV infection is an enzyme immunoassay (EIA) for HIV antibodies. The majority of tests in Australia are fourth generation assays that detect HIV antigen as well as HIV antibodies. Although false positive tests on the EIA are rare, all positive specimens are confirmed with a Western Blot. Repeat testing may be required if a woman has an indeterminate test result or HIV exposure in the preceding three months.

The potential benefits of a woman knowing her HIV status include the opportunity to receive medical care for her own health and the prevention of transmission to current or future partners and/or to her children through vertical transmission.

Interventions During Pregnancy, Delivery and Postpartum

Strategies used to reduce MTCT of HIV in Australia include antiviral therapy to the mother and newborn, caesarean delivery, and avoidance of breastfeeding.

### Table 4: HIV Intervention Summary

<table>
<thead>
<tr>
<th>Recommendation for antenatal screening</th>
<th>Routine/universal screening</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk of vertical transmission without intervention</td>
<td>13 to 40%</td>
</tr>
<tr>
<td>Recommended interventions proven to reduce vertical transmission</td>
<td>Antiretrovirals to mother antenatally and during delivery Antiretrovirals to baby Caesarean section Avoidance of breastfeeding</td>
</tr>
<tr>
<td>Benefit with intervention</td>
<td>95-97% reduction in risk (&lt;2% risk of vertical transmission)</td>
</tr>
</tbody>
</table>

*The additional benefit of caesarean section in women on cART with an undetectable maternal viral load is unknown.
Antenatal testing for HBV, HCV and HIV should be voluntary and with informed consent. Results should be conveyed in a way that is appropriate to the person’s gender, culture, behaviour, language and understanding of testing. For the latest guidance on HBV, HCV and HIV testing please refer to the National Testing Policies available at: http://testingportal.ashm.org.au/

**Summary of Antenatal Testing Recommendations**

All antenatal testing for HBV, HCV and HIV should be voluntary and with informed consent. Results should be conveyed in a way that is appropriate to the person’s gender, culture, behaviour, language and understanding of testing.

### Hepatitis B (HBV) Intervention Summary

**Recommendation for antenatal screening**
- Routine/universal screening

**Risk of vertical transmission with no intervention**
- 10% if HBeAg negative
- 90% if HBeAg positive

**Recommended interventions to reduce transmission**
- Antenatal antivirals to women with a high viral load
- Vaccine and immunoglobulin to the neonate

**Benefit of intervention**
- 95% reduction in risk

### Hepatitis C (HCV) Intervention Summary

**Recommendation for antenatal screening**
- Selective screening based on risk factors or maternal request

**Risk of vertical transmission**
- 5% if HCV RNA detected (if not also infected with HIV)

**Recommended interventions to reduce transmission**
- Avoidance of procedures that risk breaching baby’s skin or mucous membranes
- Expressing and discarding breast milk if nipples bleeding

### HIV Intervention Summary

**Recommendation for antenatal screening**
- Routine/universal screening

**Risk of vertical transmission without intervention**
- 13 to 40%

**Recommended interventions to reduce transmission**
- Antiretrovirals to mother antenatally and during delivery
- Antiretrovirals to baby
- Caesarean section*
- Avoidance of breastfeeding

**Benefit with intervention**
- 95-97% reduction in risk (<2% risk of vertical transmission)

*The additional benefit of caesarean section in women on ART with an undetectable maternal viral load is unknown.

**Avoidance of Invasive Procedures:**

It is generally recommended that procedures which may lead to a breach in the skin or mucous membranes of the baby, such as fetal scalp electrodes, fetal scalp blood sampling, vigorous aspiration of the newborn be avoided if the mother is known to have, or is at high risk of having, a blood-borne virus. Avoidance of these procedures as a strategy to prevent MTCT has not been adequately assessed in prospective trials, but there are limited data suggesting a protective benefit.61,62

Elective caesarean section has been associated with a 50% reduction in risk of vertical transmission in the era prior to cART.57,58 The added benefit of elective caesarean section in women on cART with an undetectable viral load is unknown.59

Transmission of HIV via breast milk has been reported.60 Hence, current guidelines recommend avoidance of breastfeeding in resource-rich countries where there is access to safe and affordable alternatives.51

The newborn should be tested with an HIV PCR test in the first week of life, week 6, and at 12 weeks. If all PCRs remain negative, a clinical review at 12 months is recommended and an HIV antibody test at 18 months to document seroreversion.
Antenatal Testing and BBVs – Online Learning Module

An accompanying online education module covering the most important aspects of this printed resource and incorporating interactive self-assessment activities has been developed. The aim of the online module is to discuss BBV screening in antenatal testing. To find out further information or to access this online education module please visit http://lms.ashm.org.au.
Antenatal Testing and Blood-Borne Viruses (BBVs)

SUPPLEMENTARY

References


15. Takegoshi K, Zhang W. Hepatitis B virus infections in families in which the mothers are negative but the fathers are positive for HBsAg. Hepatol Res 2006; 36: 75-7


21 Cowan SA, Bagdonaite J, Qureshi K. Universal hepatitis B screening of pregnant women in Denmark ascertains substantial additional infections: results from the first five months. Eurosurveillance 2006; 11: pii–2969.
28 Zhang H et al. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology. 2014; 60 (2) 468–476
Antenatal Testing and Blood-Borne Viruses (BBVs)


57 Giles M, Workman, C. Clinical manifestations and the natural history of HIV, HIV Management in Australasia: 125-131


Additional References


